Information Provided By: 
Fly News Breaks for September 17, 2018
AGN, RVNC
Sep 17, 2018 | 07:09 EDT
As previously reported, JMP Securities analyst Donald Ellis downgraded Revance (RVNC) to Market Perform from Outperform after Allergan (AGN) released Botox study data that he said suggests that the longer duration of activity of Revance's RT002 may be partially or primarily due to a "dose" effect. While Ellis doesn't see Allergan conducting the trials needed for an FDA label change, he does think the data will be extensively shared at medical meetings and sees it minimizing the benefit of extended duration claims for RT002 versus Botox.
News For RVNC;AGN From the Last 2 Days
There are no results for your query RVNC;AGN
